Contact
searchSearch
HMP Global
Login

Pancreatic Cancer Specialty Channel

Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
Michele Reni, MD
Conference Coverage
Neoadjuvant PAXG Significantly Improves Survival Compared to mFOLFIRNOX in Patients With Pancreatic Ductal Adenocarcinoma
07/24/2025
Michele Reni
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses...
07/24/2025
Oncology
Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Vincent Picozzi, MD
Conference Coverage
TTFields Provide Overall Survival Benefit in Locally Advanced Pancreatic Adenocarcinoma
05/31/2025
Vincent Picozzi, MD
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses...
05/31/2025
Oncology
News
FOLFIRINOX Significantly Improves Progression-Free Survival for Patients With Locally Advanced Pancreatic Cancer
05/23/2025
Stephanie Holland
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN...
05/23/2025
Oncology
News
Ablative Radiation Therapy Demonstrates Promise Among Patients With Resectable Pancreatic Ductal Adenocarcinoma
04/25/2025
Stephanie Holland
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a...
04/25/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
Conference Coverage
NALIRIFOX Dose Reductions Maintain Overall Survival in Metastatic Pancreatic Cancer
01/23/2025
Allison Casey
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory...
01/23/2025
Oncology

News

News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
Michele Reni, MD
Conference Coverage
Neoadjuvant PAXG Significantly Improves Survival Compared to mFOLFIRNOX in Patients With Pancreatic Ductal Adenocarcinoma
07/24/2025
Michele Reni
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses...
07/24/2025
Oncology
Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Vincent Picozzi, MD
Conference Coverage
TTFields Provide Overall Survival Benefit in Locally Advanced Pancreatic Adenocarcinoma
05/31/2025
Vincent Picozzi, MD
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses...
05/31/2025
Oncology
News
FOLFIRINOX Significantly Improves Progression-Free Survival for Patients With Locally Advanced Pancreatic Cancer
05/23/2025
Stephanie Holland
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN...
05/23/2025
Oncology
News
Ablative Radiation Therapy Demonstrates Promise Among Patients With Resectable Pancreatic Ductal Adenocarcinoma
04/25/2025
Stephanie Holland
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a...
04/25/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
Conference Coverage
NALIRIFOX Dose Reductions Maintain Overall Survival in Metastatic Pancreatic Cancer
01/23/2025
Allison Casey
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory...
01/23/2025
Oncology

Interactive Features

Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology
Quiz
Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?
09/08/2021
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the...
09/08/2021
Oncology
Quiz
Quiz: Do Molecularly-Matched Therapies Improve OS for Pancreatic Cancer?
08/12/2021
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments...
08/12/2021
Oncology
Quiz
Quiz: What is the Median Age of Patients Diagnosed with Pancreatic Cancer?
08/03/2021
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?
08/06/2020
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded...
08/06/2020
Oncology
Test Your Knowledge
Quiz: Adjuvant Chemoradiation for High-Risk Pancreatic Cancer
09/26/2019
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation...
09/26/2019
Oncology
Test Your Knowledge
Quiz: Durvalumab Combo Therapy for Pancreatic Cancer
08/27/2019
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______...
08/27/2019
Oncology
Test Your Knowledge
Quiz: Can Hydroxychloroquine Improve OS in Patients With Pancreatic Cancer?
07/09/2019
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent...
07/09/2019
Oncology
Test Your Knowledge
Quiz: FOLFIRINOX Outshines Gemcitabine in Pancreatic Cancer
04/17/2019
True or false: Six months of postoperative treatment with the combination of fluorouracil, leucovorin, irinotecan and oxaliplatin (ie, FOLFIRINOX) improved survival rates over conventional gemcitabine therapy in a recent study of patients...
True or false: Six months of postoperative treatment with the combination of fluorouracil, leucovorin, irinotecan and oxaliplatin (ie, FOLFIRINOX) improved survival rates over conventional gemcitabine therapy in a recent study of patients...
True or false: Six months of...
04/17/2019
Oncology
Interactive Case Report
Interactive Case Report: Ectopic ACTH Syndrome From Metastatic Pancreatic Neuroendocrine Tumor
04/04/2018
Ectopic adrenocorticotropic hormone syndrome is a rare disease with a reported incidence of 0.1 cases per million per year.
Ectopic adrenocorticotropic hormone syndrome is a rare disease with a reported incidence of 0.1 cases per million per year.
Ectopic adrenocorticotropic...
04/04/2018
Oncology

Recent News

News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
News
FOLFIRINOX Significantly Improves Progression-Free Survival for Patients With Locally Advanced Pancreatic Cancer
05/23/2025
Stephanie Holland
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN...
05/23/2025
Oncology
News
Ablative Radiation Therapy Demonstrates Promise Among Patients With Resectable Pancreatic Ductal Adenocarcinoma
04/25/2025
Stephanie Holland
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a...
04/25/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
12/04/2024
Stephanie Holland
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology
News
Perioperative Modified FOLFIRINOX Shows Promise for Pancreatic Cancer
07/31/2024
Allison Casey
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial,...
07/31/2024
Oncology
FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024
Allison Casey
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use